PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE HISTONE DEACETYLASE INHIBITOR (HDACI), FRM-0334, IN ASYMPTOMATIC CARRIERS OF, OR PATIENTS WITH FRONTOTEMPORAL LOBAR DEGENERATION (FTLD) DUE TO, PROGRANULIN GENE MUTATIONS
暂无分享,去创建一个
G. Frisoni | B. Boeve | F. Pasquier | C. Mummery | M. Onofrj | R. Vandenberghe | S. McGinnis | D. Hannequin | A. Boxer | D. Hilt | B. Borroni | I. Goodman | S. Auriacombe | G. Wisniewski | J. Swieten | H. Riordan | J. Hesterman | H. Moebius | I. Ber | H. Patzke | G. Koenig | Baruch Harris | Ken Marek | M. Grossman